National Bank of Canada’s Nektar Therapeutics NKTR Stock Holding History

National Bank of Canada’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-23	Closed	-$187	–	2835
2023 Q3	$187	Hold	23	–	–	﹤0.01%	2701
2023 Q2	$196	Hold	23	–	–	﹤0.01%	2671
2023 Q1	$238	Hold	23	–	–	﹤0.01%	2634
2022 Q4	$765	Hold	23	–	–	﹤0.01%	2607
2022 Q3	$1K	Hold	23	–	–	﹤0.01%	2611
2022 Q2	$1K	Hold	23	–	–	﹤0.01%	2702
2022 Q1	$2K	Hold	23	–	–	﹤0.01%	2703
2021 Q4	$5K	Buy	+23	New	+$4.99K	﹤0.01%	2537

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

National Bank of Canada's NKTR Position: Q4 2023 in Review

National Bank of Canada sold out of Nektar Therapeutics (NKTR) in Q4 2023, closing a stake of 23 shares — an estimated $187 sold.

National Bank of Canada first reported a position in NKTR in Q4 2021 and held it in 8 quarters. The position peaked at $5K in Q4 2021. 125 funds tracked by Wall St. Rank hold NKTR as of Q4 2023.

National Bank of Canada reported no remaining Nektar Therapeutics position as of Q4 2023 after selling out during the quarter.
National Bank of Canada sold 23 Nektar Therapeutics shares in Q4 2023, an estimated $187.
National Bank of Canada first reported a position in Nektar Therapeutics in Q4 2021 and held it in 8 quarters.
National Bank of Canada's Nektar Therapeutics position peaked at $5K in Q4 2021.
125 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2023.

Based on National Bank of Canada's 13F filing for Q4 2023, filed 6 Feb 2024.